MarketCapExport financials
TG Therapeutics (TGTX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
TG Therapeutics Income Statement 2025-2009 | TGTX
Brief overview of financial results at TG Therapeutics
The overview follows changes across a five-year period. Revenue at TG Therapeutics moved from $152 thousand in 2020 to $616 million in 2025. The total change was +405352%, with a CAGR of approximately 426.7%. The company expanded its revenue base at a high speed.
The five-year EBITDA result moved by +145.1%: from −273 million dollars to 123 million dollars. EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin moved from −179892.1% to 20%. The company improved its ability to convert sales into EBITDA.
The final result was −279 million dollars initially and 447 million dollars in the final year. The trajectory reversed from a loss to positive earnings.
The market value of the business moved from $5.6 billion to $4.3 billion, or −22.1%. The market has not yet confirmed the improvement in fundamentals.
Overall conclusion
The results present an uneven picture without one dominant signal. The positive side is supported by net-income growth, revenue expansion and an improving EBITDA margin. The most visible risks are lower investor confidence. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement TG Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
4.34 B | 4.9 B | 2.42 B | 2.05 B | 1.53 B | 5.57 B | 1.26 B | 327 M | 726 M | 230 M | 373 M | 485 M | 156 M | 47.9 M | 1.95 M | - | - |
Shares |
144 M | 145 M | 142 M | 135 M | 132 M | 115 M | 88.4 M | 75.5 M | 62.1 M | 49 M | 45.6 M | 34.1 M | 25.4 M | 13.1 M | 1.93 M | - | - |
Historical Prices |
30 | 33.8 | 17.1 | 15.1 | 11.6 | 48.3 | 14.2 | 4.1 | 11.5 | 4.8 | 8.17 | 14.2 | 6 | 3.71 | 3.38 | 183 | - |
Net Income |
447 M | 23.4 M | 12.7 M | -198 M | -348 M | -279 M | -173 M | -173 M | -118 M | -78.3 M | -62.9 M | -55.8 M | -20.5 M | -18.1 M | -853 K | - | - |
Revenue |
616 M | 329 M | 234 M | 2.78 M | 6.69 M | 152 K | 152 K | 152 K | 152 K | 152 K | 152 K | 152 K | 152 K | 19 K | - | - | - |
Cost of Revenue |
101 M | 38.5 M | 14.1 M | 265 K | 790 K | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
123 M | 41.9 M | 20.6 M | -218 M | -345 M | -274 M | -169 M | -174 M | -119 M | -79 M | -63.2 M | -55.7 M | -23 M | -26.9 M | -882 K | - | - |
Interest Expense |
10.8 M | 7.69 M | 12.6 M | 10.2 M | 5.64 M | 6.33 M | 5.29 M | 877 K | 845 K | - | 973 K | 931 K | 953 K | 906 K | 7.1 K | - | - |
EBITDA |
123 M | 42 M | 20.8 M | -218 M | -344 M | -273 M | -169 M | -174 M | -119 M | -78.9 M | -63.2 M | -55.7 M | -20.2 M | -25.8 M | -882 K | - | - |
Operating Expenses |
- | - | - | 196 M | - | 274 M | 169 M | 175 M | 119 M | 79.1 M | 63.3 M | 55.9 M | 20.3 M | 25.8 M | 882 K | - | - |
General and Administrative Expenses |
232 M | 154 M | 123 M | 95.5 M | 128 M | 108 M | 20.8 M | 20.8 M | 22 M | 12.6 M | 19.9 M | 24.5 M | 7.7 M | 5.24 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement TG Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
142 M | 144 M | 145 M | 147 M | 147 M | 156 M | 145 M | 145 M | 146 M | 151 M | 143 M | 142 M | 140 M | 146 M | 135 M | 135 M | 134 M | 143 M | 132 M | 132 M | 132 M | 141 M | 119 M | 112 M | 105 M | 109 M | 89.7 M | 86.8 M | 81.2 M | 83.9 M | 78.2 M | 74.3 M | 70.6 M | 73.1 M | 65.1 M | 63.3 M | 53.2 M | 56.8 M | 49.2 M | 48.8 M | 48.9 M | 54.1 M | 47.9 M | 45.3 M | 41.1 M | 44.9 M | 34.2 M | 33 M | 30.1 M | 34.3 M | 27.7 M | 22.5 M | 22 M | 25.8 M | 15.8 M | 11.8 M | 5.06 M | 5.06 M | 2.63 M | 1.82 M | 5.06 M |
Net Income |
7.78 M | 19.8 M | 391 M | 28.2 M | 5.06 M | - | 3.88 M | 6.88 M | -10.7 M | - | 114 M | -47.6 M | -39.2 M | - | -35.8 M | -40.5 M | -69 M | - | -85.6 M | -78.5 M | -90.6 M | - | -87.2 M | -52.9 M | -51.1 M | -39.6 M | -61.9 M | -36.2 M | -35.2 M | -53.9 M | -34 M | -44.1 M | -41.5 M | -30.9 M | -31.5 M | -28.4 M | -27.7 M | -23.7 M | -24.8 M | -15.9 M | -13.8 M | -17.6 M | -13.7 M | -17.1 M | -14.6 M | -18.8 M | -17.5 M | -12 M | -7.55 M | - | -4.56 M | -6.58 M | -3.67 M | - | -2.46 M | -1.89 M | -10.3 M | - | -28.6 K | -282 K | - |
Revenue |
240 M | 205 M | 162 M | 141 M | 121 M | - | 83.9 M | 73.5 M | 63.5 M | - | 166 M | 16.1 M | 7.8 M | - | 94 K | 594 K | 2.02 M | - | 2.03 M | 1.54 M | 793 K | - | 38 K | 38 K | 38 K | - | 38 K | 38 K | 38 K | - | 38 K | 38 K | 38 K | - | 38 K | 38 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
41.2 M | 33.5 M | 28.1 M | 18.9 M | 15.5 M | - | 9.34 M | 8.3 M | 5.44 M | - | 3.51 M | 1.91 M | 857 K | - | 2 K | - | - | - | - | - | 139 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
21.7 M | 34.8 M | 29.4 M | 34.8 M | 8.62 M | - | 12.4 M | 8.82 M | -9.27 M | - | 115 M | -44.7 M | -37 M | - | -35 M | -38.9 M | -66.9 M | - | -85.1 M | -77.5 M | -89.2 M | - | -85.7 M | -50.8 M | -50.2 M | - | -60.9 M | -35.5 M | -34.7 M | - | -34.3 M | 44.3 M | -41.6 M | - | -31.6 M | -28.4 M | -27.7 M | - | -24.9 M | -16 M | -14 M | - | -13.8 M | -17.1 M | -14.6 M | - | -17.4 M | -12 M | -7.61 M | - | -4.65 M | -6.63 M | -3.71 M | - | -2.71 M | -3.1 M | -17.4 M | - | -30.1 K | -297 K | - |
Interest Expense |
5.13 M | 2.39 M | 3.26 M | 2.79 M | 3.6 M | - | 2.67 M | 1.71 M | 880 K | - | 2.86 M | 691 K | 2.84 M | - | 1.65 M | 3.02 M | 2.66 M | - | 1.04 M | 1.62 M | 1.9 M | - | 1.61 M | 2.23 M | 1.2 M | - | 1.54 M | 1.08 M | 774 K | - | 221 K | - | - | - | - | - | - | - | 212 K | 221 K | 242 K | - | 247 K | 247 K | 238 K | - | 235 K | 235 K | 226 K | - | 241 K | 240 K | 231 K | - | 229 K | 228 K | 220 K | - | - | - | - |
EBITDA |
21.8 M | 34.8 M | - | - | 8.63 M | - | - | - | -9.24 M | - | - | - | -36.9 M | - | -34.7 M | -38.8 M | -66.8 M | - | -84.9 M | -77.4 M | -89.1 M | - | -85.6 M | -50.8 M | -50.2 M | - | -60.8 M | -35.5 M | -34.7 M | - | -34.3 M | 44.4 M | -41.6 M | - | -31.5 M | -28.4 M | -27.6 M | - | -24.9 M | -16 M | -14 M | - | -13.8 M | -17.1 M | -14.6 M | - | -17.4 M | -12 M | -7.6 M | - | -4.65 M | -6.63 M | -3.71 M | - | -2.71 M | -3.1 M | -17.4 M | - | -30.1 K | -297 K | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | 60.7 M | 44.8 M | - | 35.1 M | 39.5 M | 68.9 M | - | 87.2 M | 79 M | 90 M | - | 85.8 M | 50.9 M | 50.3 M | 38 M | 60.9 M | 35.6 M | 34.7 M | 54.2 M | 34.4 M | 44.4 M | 41.6 M | 31.1 M | 31.6 M | 28.5 M | 27.7 M | 24.1 M | 25 M | 16.1 M | 14 M | 17.7 M | 13.9 M | 17.1 M | 14.6 M | 18.8 M | 17.5 M | 12 M | 7.64 M | - | 4.69 M | 6.67 M | 3.75 M | - | 2.71 M | 3.1 M | 17.4 M | - | 30.1 K | 297 K | - |
General and Administrative Expenses |
82.1 M | 88.2 M | 63.4 M | 55.6 M | 50.3 M | - | 42 M | 38.8 M | 34.6 M | - | 32.8 M | 30.7 M | 28.1 M | - | 14.3 M | 12.6 M | 20.6 M | - | 34.9 M | 34 M | 26.8 M | - | 11.6 M | 8.62 M | 5.17 M | - | 2.32 M | 2.31 M | 1.95 M | - | 1.78 M | 2.31 M | 2.12 M | - | 1.4 M | 1.53 M | 1.33 M | - | 1.25 M | 1.45 M | 1.1 M | - | 1.09 M | 1 M | 1 M | - | 890 K | 707 K | 904 K | - | 551 K | 632 K | 651 K | - | 462 K | 396 K | 455 K | - | 14.2 K | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company TG Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
France
Israel
Australia
Britain
